Uk.ResellerClub Launches New Promotion Offering Free .CO.UK Domains With Hosting Packages

LONDON, May 10, 2013 /PRNewswire/ --  Web Presence products provider Uk.ResellerClub have...

Wirecard Gains SriLankan Airlines As A New Customer In Asia

MUNICH, Germany, April 30, 2013 /PRNewswire/ -- Wirecard AG, provider of a globally accepted payment...

Global Payments Continues Focus On Mobile Payments In The UK

LONDON, March 28, 2013 /PRNewswire/ -- Global Payments is further strengthening its mobile payment...

Induced Pluripotent Stem Cell Industry Report

Stem cell research and experimentation has been in process for well over five decades and they...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »


ArQule, Inc. and Daiichi Sankyo Co., Ltd. announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC). 

 Jackpotjoy Slots is a social game provider on Facebook that has so far attracted more than 6 million players. 

HIGH WYCOMBE, England, June 6, 2012  -- Findings from a psoriasis clinical development program for a biologic following patients continuously for five years provide insights on the long-term response and safety profile of ustekinumab.

New efficacy and safety data from the Phase 3 PHOENIX 1 study, one of two pivotal registration trials, showed that maintenance treatment with STELARABlack Triangle Drug (ustekinumab) for up to five years of follow up resulted in consistent, significant clinical response in adults with moderate to severe plaque psoriasis.[1] The data are presented today at the 9th Annual European Academy of Dermatology and Venereology (EADV) Spring Symposium in Verona, Italy.

BERLIN, June 6, 2012 -- Abbott today announced results from two long-term, open-label studies, which evaluated the results of HUMIRA® (adalimumab) treatment for up to 10 years in patients with long-standing, moderate-to-severe rheumatoid arthritis (RA). These 10-year HUMIRA studies, DE019 and DE020, are among the longest, open-label trials in RA. Results presented at the European League Against Rheumatism (EULAR) 2012 Congress in Berlin, Germany, include information on clinical response, radiographic inhibition and physical function data in patients with long-standing RA.

NANJING, China, June 1, 2012 -- ET Solar Group Corp. has announced construction execution of two ground-mounted PV power plants in Germany with total installed capacity of 12.6MW.

ET Solar's subsidiary ET Solutions AG is the EPC contractor for the 7.6MW and 5MW PV plants that are located in Hohen Wangelin (150 kilometers north of Berlin) and Ratzlingen (30 kilometers east of Wolfburg) respectively. Project construction is well on the way and the completion is expected by the end of June this year.